Diabetes: Page 3
-
Courtesy of Dexcom
Dexcom’s over-the-counter nod sets stage for broader CGM use
The FDA’s decision allows people who don’t take insulin, including those who don’t have diabetes, to use the devices without a prescription.
By Elise Reuter • March 7, 2024 -
Courtesy of Roche
Roche to take on Abbott, Dexcom with its first CGM
The new sensor is designed to last for 14 days but requires finger-stick calibration.
By Nick Paul Taylor • March 7, 2024 -
Courtesy of Dexcom, Nick Jonas Super Bowl kit
Dexcom receives FDA clearance for first OTC glucose sensor
The diabetes tech firm is tailoring its software to the 25 million people in the U.S. who have Type 2 diabetes and do not use insulin.
By Nick Paul Taylor • March 6, 2024 -
Courtesy of Dexcom
Dexcom, Novo Nordisk call for FDA input on digital diabetes detection devices
The companies want clarity on what evidence would be needed for new technologies to detect undiagnosed Type 2 diabetes or prediabetes.
By Nick Paul Taylor • March 4, 2024 -
Courtesy of Insulet Corp.
Insulet sizes up competition as Tandem, Medtronic plan new insulin patch-pumps
Insulet CEO Jim Hollingshead said the company is “very confident” in its competitive position as rivals develop their own patch pumps.
By Elise Reuter • Feb. 29, 2024 -
Sara Silbiger via Getty Images
FDA warns against using smart wearables that claim to measure blood sugar
Unauthorized smartwatches and smart rings are “manufactured by dozens of companies and sold under multiple brand names,” according to the agency.
By Nick Paul Taylor • Feb. 23, 2024 -
Courtesy of Insulet Corp.
Insulet wins CE mark for integration of insulin pump with Abbott CGM
The clearance positions Insulet to sell the integrated Type 1 diabetes product in Europe beginning in the first half of the year.
By Nick Paul Taylor • Feb. 8, 2024 -
Sarah Silbiger via Getty Images
FDA extends deadline for comments on role of digital health in diabetes detection
The agency is seeking answers on how digital health technologies could be used in the detection of prediabetes and Type 2 diabetes.
By Nick Paul Taylor • Jan. 31, 2024 -
Courtesy of Abbott
Abbott says all four segments stronger than pre-pandemic
CEO Robert Ford said investing in its base business using COVID-19 testing revenues was “absolutely the right strategy.”
By Elise Reuter • Jan. 24, 2024 -
Mario Tama via Getty Images
3 bellwether companies to watch as medtech earnings season begins
J&J, Intuitive Surgical and Abbott kick off this week with fourth-quarter reports.
By Nick Paul Taylor • Jan. 22, 2024 -
Permission granted by Abbott
Abbott CEO talks diabetes market, device pricing at J.P. Morgan conference
CEO Robert Ford is “very confident” in Abbott’s ability to pass $10 billion in sales of its Libre continuous glucose monitor products by 2028.
By Elise Reuter • Jan. 10, 2024 -
Permission granted by Medtronic
Medtronic focused on delivering durable revenue and profit growth
“Our top priority is restoring our earnings power, full stop,” CEO Geoff Martha said Monday at the J.P. Morgan Healthcare Conference.
By Susan Kelly • Jan. 9, 2024 -
Permission granted by Dexcom
Dexcom plans to launch new CGM this summer for people who don’t take insulin
The company also shared earnings expectations for 2024 at the J.P. Morgan Healthcare Conference.
By Elise Reuter • Jan. 9, 2024 -
Courtesy of Tandem Diabetes Care
Abbott, Tandem launch new hybrid closed-loop insulin delivery system
Competitor Medtronic also received a CE mark for a new CGM sensor that can integrate with its 780G pump.
By Elise Reuter • Jan. 8, 2024 -
Martin Barraud via Getty Images
BTIG analysts optimistic medtech will rebound in 2024 after ‘string of rough years’
Rising interest rates, fears about the impact of GLP-1 drugs and “choppy supply-chain dynamics” dragged on the industry this year, the analysts wrote.
By Nick Paul Taylor • Dec. 18, 2023 -
Courtesy of Tandem Diabetes Care
Tandem completes US launch of revamped diabetes management platform
The platform, Tandem Source, combines the features of the company’s legacy t:connect offerings with new data reports.
By Nick Paul Taylor • Dec. 15, 2023 -
Courtesy of EOFlow
Medtronic scraps plans to buy insulin patch-pump maker EOFlow
Medtronic cited “multiple breaches” of the companies’ agreements. EOFlow has been embroiled in patent lawsuits with Insulet this year.
By Elise Reuter • Dec. 7, 2023 -
Courtesy of Dexcom, Nick Jonas Super Bowl kit
Dexcom, Hologic picked to outperform in 2024: William Blair
For the medtech industry overall, the analysts wrote that procedure volume growth is likely to normalize after declining due to the COVID-19 pandemic.
By Nick Paul Taylor • Dec. 7, 2023 -
Sara Silbiger via Getty Images
Unomedical recall of infusion sets tagged as Class I by FDA
The company notified Tandem Diabetes Care, its sole consignee, in October of the risk for infusion sets to detach from insulin pumps, disrupting insulin delivery.
By Nick Paul Taylor • Nov. 28, 2023 -
Permission granted by Embecta
Q&AEmbecta CEO Dev Kurdikar talks about growth expectations, GLP-1s
The CEO said the company’s growth expectations have not changed in the near term, even with the rise of weight loss drugs.
By Elise Reuter • Nov. 21, 2023 -
Permission granted by Abbott
Q&AAbbott Diabetes Care CMO Mahmood Kazemi on expanding CGM access
Kazemi hopes anyone with diabetes will be able to access the technology, even people who don’t take insulin.
By Elise Reuter • Nov. 17, 2023 -
Douglas Cliff via Getty Images
Wegovy study details revive debate over GLP-1 impact on devices
The data confirmed a cardiovascular benefit for heart patients and showed the drug could help pre-diabetic patients control their blood sugar.
By Susan Kelly • Nov. 13, 2023 -
Courtesy of Dexcom
NICE backs use of hybrid closed loop systems for Type 1 diabetes, if companies offer discounts
The group’s recommendation gives around 150,000 people with Type 1 diabetes living in England the chance to access the systems, according to an NHS England official.
By Nick Paul Taylor • Nov. 9, 2023 -
Courtesy of Tandem
Diabetes tech firms focusing on Type 2 patients
Leaders from Abbott, Dexcom, Tandem and Insulet expect Type 2 uptake of their insulin pumps and CGMs to accelerate as coverage improves and new devices reach the market.
By Elise Reuter • Nov. 7, 2023 -
Courtesy of Medtronic
5 companies to watch as medtech earnings wind down
Zimmer Biomet, BD, Masimo, Illumina and Medtronic are all set to report financial results as the medtech earnings season draws to a close.
By Nick Paul Taylor • Nov. 6, 2023
Previous
